Symptomatic treatment of dyspnea in advanced cancer patients
- 639 Downloads
Dyspnea is a common, very distressing symptom in advanced cancer patients that challenges them, their relatives, and healthcare professionals. This narrative review summarizes important literature dealing with the evidence for opioids, benzodiazepines, oxygen, and steroids for treating dyspnea in advanced cancer patients.
A selective literature search was undertaken in PubMed, Embase, and the Cochrane Library and extended with literature from the reference lists of included studies up to April 2016. Inclusion criteria were that patients were suffering from advanced cancer and were receiving either opioids, benzodiazepines, corticosteroids, or oxygen. The outcome of interest was the reduction of dyspnea measured via a visual analogue scale (VAS), a numerical rating scale (NRS), or a Borg scale. This narrative review describes in detail the findings of 13 studies.
Nine studies deal with the effectiveness of opioids for reducing dyspnea in advanced cancer patients. Five of these found a significant benefit to the use of opioids compared to a placebo. Three found no significant improvements, and two favored combinations of opioids and benzodiazepines. Few high-quality studies were available that used benzodiazepines (n = 3, no difference, significant improvement with midazolam + morphine, significant difference for midazolam) or oxygen (n = 2, both without significant difference). Only one study examined treating dyspnea with steroids in patients with advanced cancer, and that study indicated a benefit of steroids compared to a placebo.
Opioids are the drug of choice for treating refractory dyspnea in advanced cancer patients. Neither benzodiazepines nor oxygen showed significant benefit. In addition, there is insufficient literature available to draw a conclusion about the effectiveness of steroids for treating persistent dyspnea in advanced cancer patients.
KeywordsDyspnea Advanced cancer Opioids Benzodiazepines Steroids
Chronic obstructive pulmonary disease
Edmonton Symptom Assessment Scale
European Society for Medical Oncology
Numeric rating scale
Randomized controlled trials
Visual analog scale
Conflict of interest
M. Strieder, M. Pecherstorfer, and G. Kreye declare that they have no competing interests.
- 2.Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF): Palliativmedizin für Patienten mit einer nicht heilbaren Krebserkrankung L‑, version 1.0, AWMF-Registernummer: 128/001OL.Google Scholar
- 8.Bulbul Y, Ozlu T, Arinc S, Ozyurek BA, Gunbatar H, Senturk A, et al. Assesment of palliative care in lung cancer in Turkey (ASPECT study). Eur Respir J. 2015; https://doi.org/10.1183/13993003.congress-2015.PA4843.CrossRefGoogle Scholar
- 14.Simon ST, Higginson IJ, Booth S, Harding R, Weingartner V, Bausewein C. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev. 2016; https://doi.org/10.1002/14651858.CD007354.pub3.CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Davis CPK, A’Hern R, et al. Single dose randomised controlled trial of nebulised morphine in patients with cancer related breathlessness. Palliat Med. 1996;10:64–5.Google Scholar
- 27.Harrison, TJR. A comparison of the effectiveness of oral lorazepam and placebo in relieving breathlessness associated with advanced cancer [dissertation]. Bristol: Bristol University, 2004.Google Scholar
- 29.Navigante. Morphine versus midazolam as upfront therapy to relief dyspnea in ambulatory cancer patients while its underlying cause is sought or treated. (unpublished).Google Scholar